BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 18254285)

  • 1. [Seric soluble interleukin-2 receptor alpha in nasopharyngeal carcinoma in Tunisia. Prospective study about 45 cases].
    Jmal A; Ghanem A; Boussen H; Gara Y; Abaza H; Gara S; Harzallah L; Ladgham A; Guemira F
    Tunis Med; 2007 Aug; 85(8):651-4. PubMed ID: 18254285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Contribution of serum Cyfra 21-1 in nasopharyngeal carcinoma in Tunisia].
    Jmal A; Boussen H; Abdennebi M; Gara S; Harzallah L; Gritli S; Ladgham A; Guemira F; Ghanem A
    Bull Cancer; 2004 Apr; 91(4):369-72. PubMed ID: 15242321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of measuring levels of tumor necrosis factor-alpha and soluble interleukin-2 receptor in nasopharyngeal carcinoma.
    Hsiao SH; Lee MS; Lin HY; Su YC; Ho HC; Hwang JH; Lee CC; Hung SK
    Acta Otolaryngol; 2009 Dec; 129(12):1519-23. PubMed ID: 19922107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Serum lactate dehydrogenase and its isoenzymes in nasopharyngeal carcinoma in Tunisia].
    Jmal A; Abdennebi M; Boussen H; Abaza H; Gara S; Bendjemana K; Harzallah L; Guemira F; Ghanem A
    Tunis Med; 2005 Apr; 83(4):218-20. PubMed ID: 15966667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis.
    Bleesing J; Prada A; Siegel DM; Villanueva J; Olson J; Ilowite NT; Brunner HI; Griffin T; Graham TB; Sherry DD; Passo MH; Ramanan AV; Filipovich A; Grom AA
    Arthritis Rheum; 2007 Mar; 56(3):965-71. PubMed ID: 17328073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble interleukin-2 receptor and metalloproteinase-9 expression in head and neck cancer: prognostic value and analysis of their relationships.
    El Houda Agueznay N; Badoual C; Hans S; Gey A; Vingert B; Peyrard S; Quintin-Colonna F; Ravel P; Bruneval P; Roncelin S; Lelongt B; Bertoglio J; Fridman WH; Brasnu D; Tartour E
    Clin Exp Immunol; 2007 Oct; 150(1):114-23. PubMed ID: 17680822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma.
    Bien E; Balcerska A
    Scand J Immunol; 2009 Nov; 70(5):490-500. PubMed ID: 19874554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrophage inflammatory protein-3alpha is a novel serum marker for nasopharyngeal carcinoma detection and prediction of treatment outcomes.
    Chang KP; Hao SP; Chang JH; Wu CC; Tsang NM; Lee YS; Hsu CL; Ueng SH; Liu SC; Liu YL; Wei PC; Liang Y; Chang YS; Yu JS
    Clin Cancer Res; 2008 Nov; 14(21):6979-87. PubMed ID: 18980993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of soluble interleukin-2 receptor alpha (sIL-2Ralpha) as a predictor of outcome in brucellosis.
    Makis AC; Galanakis E; Hatzimichael EC; Papadopoulou ZL; Siamopoulou A; Bourantas KL
    J Infect; 2005 Oct; 51(3):206-10. PubMed ID: 16230217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
    Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical relevance of elevated levels of serum soluble interleukin-2 receptor alpha (sIL-2Rα) in patients with non-Hodgkin's lymphoma.
    Jo SA; Hwang SH; Chang CL; Kim SY; Shin HJ; Chung JS; Sol MY; Lee EY
    Korean J Lab Med; 2010 Dec; 30(6):600-5. PubMed ID: 21157146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma osteopontin, hypoxia, and response to radiotherapy in nasopharyngeal cancer.
    Hui EP; Sung FL; Yu BK; Wong CS; Ma BB; Lin X; Chan A; Wong WL; Chan AT
    Clin Cancer Res; 2008 Nov; 14(21):7080-7. PubMed ID: 18981006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble interleukin-2 receptor as a clinical parameter for nasopharyngeal carcinoma.
    Hsu MM; Chen YJ; Chang YL; Ko JY; Sheen TS
    Asian Pac J Allergy Immunol; 1995 Jun; 13(1):1-4. PubMed ID: 7488337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endogenous tumor necrosis factor-alpha in patients with nasopharyngeal carcinoma.
    Yadav M
    Southeast Asian J Trop Med Public Health; 1991 Mar; 22(1):123-6. PubMed ID: 1948253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of primary tumor volume in patients with nasopharyngeal carcinoma treated by definitive radiation therapy.
    Shen C; Lu JJ; Gu Y; Zhu G; Hu C; He S
    Laryngoscope; 2008 Jul; 118(7):1206-10. PubMed ID: 18418278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum soluble interleukin-2 receptor alpha in systemic lupus erythematosus.
    El-Shafey EM; El-Nagar GF; El-Bendary AS; Sabry AA; Selim AG
    Iran J Kidney Dis; 2008 Apr; 2(2):80-5. PubMed ID: 19377213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum level of soluble interleukin-2 receptor alpha as a predictor of treatment response in brucellosis.
    Kahbazi M; Rezapour H; Jafari F; Arjomandzadegan M; Sofian M; Zarinfar N; Sarmadiayan H; Najmi AR
    J Ayub Med Coll Abbottabad; 2012; 24(2):44-6. PubMed ID: 24397050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of platelet activating factor and butyrate on the expression of interleukin-2 receptor alpha in nasopharyngeal carcinoma cells.
    Tsai MH; Chiou SH; Chow KC
    Int J Oncol; 2001 Nov; 19(5):1049-55. PubMed ID: 11605008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Serum acute phase proteins in nasopharyngeal carcinoma and laryngeal cancers].
    Chen P
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 1989; 24(3):174-6, 190. PubMed ID: 2484505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy: report on the 3-year outcome of a prospective series.
    Lin S; Pan J; Han L; Zhang X; Liao X; Lu JJ
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1071-8. PubMed ID: 19362784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.